Publication date: Dec 01, 2026
Respiratory syncytial virus (RSV) can cause serious disease in older adults (OAs), particularly those with comorbidities. It is a leading cause of acute respiratory illness and lower respiratory tract infections in adults ≥60 years. Its impact on morbidity, mortality, and healthcare systems is becoming evident. Questions about the burden of disease (BoD) are raised due to underdiagnosis and the similarity with other respiratory illnesses. First opportunities for prevention came in 2023 and 2024, with vaccines approved for ≥60 years, expanding eligibility to additional age groups. A modified Delphi approach through a questionnaire survey and virtual consensus workshop with 27 experts in respiratory and infectious diseases from 12 emerging market countries was done to reach consensus on diagnosis, prevention, and treatment of RSV in OAs. The panel recommends the introduction of a universal vaccination program for all adults aged ≥70 years, and vaccination for all adults aged ≥60 years with comorbidities. The need for increased awareness, better testing, and national and international guidelines was also agreed. The agreements highlight that RSV vaccination for OAs should be prioritized. Educating clinicians and patients, improving surveillance, and integrating RSV vaccination into health policies are key to reducing BoD in OAs.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | RSV infections |
| disease | MESH | OAs |
| disease | MESH | infectious diseases |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | Respiratory Tract Infections |